VESIcare LS 5 mg in 5 mL Oral Suspension
RxNorm 2375325
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2375325 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: VESIcare LS 5 mg in 5 mL Oral Suspension.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
Solifenacin succinate 1 mg/ML Oral Suspension [Vesicare]
(Atom ID: 12408306)
SYPrescribable
Synonym (SY):
Vesicare 1 mg/ML Oral Suspension
(Atom ID: 12408308)
PSNPrescribable
Prescribable Name (PSN):
VESIcare LS 5 mg in 5 mL Oral Suspension
(Atom ID: 12408312)
SYPrescribable
Synonym (SY):
Vesicare LS 5 mg per 5 mL Oral Suspension
(Atom ID: 12408309)
Patient Education
Solifenacin
Solifenacin (VESIcare) is used to treat overactive bladder (a condition in which the bladder muscles contract uncontrollably and cause frequent urination, urgent need to urinate, and inability to control urination). Solifenacin (VESIcare LS) is used to treat neurogenic detrusor overactivity (a bladder control condition caused by brain, spinal cord or nerve problem) in children 2 years of age and older. Solifenacin is in a class of medications called antimuscarinics. It works by relaxing the bladder muscles.
[Learn More]
* Please review the disclaimer below.